Spruce Biosciences Inc (NAS:SPRB)
$ 0.4356 0.0106 (2.49%) Market Cap: 17.99 Mil Enterprise Value: -48.38 Mil PE Ratio: 0 PB Ratio: 0.30 GF Score: 35/100

Spruce Biosciences Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 - Nov 17, 2022 / NTS GMT
Release Date Price: $1.05
Tiago Fauth
Credit Suisse Group AG - Analyst

Great. So welcome, everyone, to the 31st Annual Healthcare Conference at Credit Suisse. I am Tiago Fauth; I am a biotech analyst here at Credit Suisse. We're joined today by Spruce Bio. Javier, CEO, is going to do a quick presentation, with some Q&A towards the end.

Javier Szwarcberg
Spruce Biosciences Inc. - CEO

Thank you. Thank you, Tiago. My name is Javier Szwarcberg. It's a real pleasure to be here. I am the CEO of Spruce. I'm going to move forward from our forward-looking statements, which I'll be making along my presentation. And I wanted to first tell you what Spruce is. We are an early-stage biotech company, currently developing tildacerfont for the treatment of CAH as well as PCOS. I'll be spending the majority of my time talking to you about CAH. In the latter part of my deck, I'll discuss some pediatrics -- our pediatric efforts and our PCOS effort.

So CAH is a large, fairly large, market opportunity. It's a $3 billion market opportunity with a high unmet medical need, which was

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot